More VGPRs Seen With Zanubrutinib Versus Ibrutinib in Waldenstrom Macroglobulinemia

In cohort 1 of the phase III ASPEN trial, zanubrutinib demonstrated a higher very good partial response rate and a more tolerable safety profile compared with ibrutinib in patients with Waldenström macroglobulinemia. However, the study missed its primary end point of statistically significant superiority in complete response and VGPR rates, according to a press release from BeiGene, Ltd,…

Read the full article here

Related Articles